Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Chemotherapy and Pharmacology is Scopus-indexed (Q2, CiteScore 4.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media Deutschland GmbH.
Checked against the index lists dated .
ISSN 0344-5704Verify ISSN ↗1432-0843Verify ISSN ↗
Publisher: Springer Science and Business Media Deutschland GmbH
Cost to publish: About US$4,390 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 112 / 278 | 59th | Q2 |
| Oncology | 180 / 428 | 58th | Q2 |
| Pharmacology | 161 / 328 | 51st | Q2 |
| Toxicology | 71 / 131 | 46th | Q3 |
| Cancer Research | 143 / 233 | 38th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1978–present, best quartile Q2, CiteScore 4.6.
Cancer Chemotherapy and Pharmacology is Q2 in Pharmacology (medical) (rank 112 of 278), Q2 in Oncology (rank 180 of 428) and Q2 in Pharmacology (rank 161 of 328), by CiteScore 2025. It is ranked in 5 subject areas in all.
Cancer Chemotherapy and Pharmacology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.6, which places it in quartile Q2 at the 59th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.851, quartile Q2, with an H-index of 132.
The publisher lists an article processing charge of about US$4,390 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Chemotherapy and Pharmacology is published by Springer Science and Business Media Deutschland GmbH. Its print ISSN is 0344-5704 and its online ISSN is 1432-0843.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Chemotherapy and Pharmacology has an h-index of 155 and a 2-year mean of 2.26 citations per paper (OpenAlex). Its Scopus CiteScore is 4.6, quartile Q2. On 2-year citations it ranks #117 of 271 Scopus journals in Pharmacology (medical).
Cancer Chemotherapy and Pharmacology published 112 papers in 2025; its busiest recent year was 2017 with 279. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from Japan (16.8%), United States (12.6%) and China (12.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 23 retracted papers are recorded (2.3 per 1,000 papers). The Problematic Paper Screener flags 4 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.